Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial.
Weickert TW, Jacomb I, Lenroot R, Lappin J, Weinberg D, Brooks WS, Brown D, Pellen D, Kindler J, Mohan A, Wakefield D, Lloyd AR, Stanton C, O'Donnell M, Liu D, Galletly C, Shannon Weickert C.
Weickert TW, et al.
Brain Behav Immun. 2024 Jan;115:191-200. doi: 10.1016/j.bbi.2023.10.012. Epub 2023 Oct 15.
Brain Behav Immun. 2024.
PMID: 37848096
Free article.
Clinical Trial.